Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Davide Matino, Federico Germini, Anthony K. C. Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N. Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Haemophilia
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet